- Expands footprint in Malaysia
- Acquisition to bolster BSV’s dominance in women’s health and reproductive therapy
Chennai/New Delhi, December 15,2022:
Bharat Serums and Vaccines Limited (BSV), a leading biopharmaceutical company in India has entered into a definitive agreement to acquire Firstline Pharmaceuticals Sdn. Bhd and Genomicks Sdn Bhd, to augment its presence in women’s health and reproductive therapy in Malaysia. Following the acquisition, the two companies will be held by BSV. Incorporated in 2007, Firstline Pharmaceuticals Sdn. Bhd. is one of the leading distributors of fertility treatment in Malaysia. Genomicks Sdn Bhd was incorporated in 2016 and currently distributes medical devices in Malaysia. The companies distribute a wide range of products which include FoliculinTM, Hucog®, Humog®, Profortil, Fortelle+Omega 3.
Speaking on the acquisition, Rahul Adakmol, COO-International Operations, BSV, said “We continue to remain one of the few Indian biopharma majors with a strong global footprint. We are delighted to acquire Firstline Pharmaceuticals Sdn. Bhd and Genomicks Sdn Bhd as this accelerates our business goal of deepening our presence in South-East Asia. Keeping women at the core of our business activities, we are committed to bringing our broad portfolio of treatment options, devices, and advanced fertility treatments, which deliver improved health outcomes and have a measurable impact on their wellbeing.”
“We are delighted with this partnership with BSV as this not only expands BSV’s offerings in women’s health but most importantly, works towards bringing more products that will improve the lives of women in Malaysia. Over the years, we have established our presence in Malaysia and have played a critical role in bringing safer treatments and cures to our people. We are confident that this partnership will open opportunities in growing BSV’s presence in other business segments” said Logen Singam and Chitra Santhirarajan, Founders- Firstline Pharmaceuticals Sdn. Bhd and Genomicks Sdn Bhd, Malaysia.